Compliance updated on Sep 10, 2026 Screened by AAOIFI-Certified Shariah Advisor & Auditor

Financial data updated nightly

Ironwood Pharmaceuticals, Inc.

IRWD ✗ NOT COMPLIANTFree checks used up today ☆ Track — members

NASDAQ · Healthcare · Pharmaceuticals ·

USA Small Cap Analyst: BUY

Last Close

$4.41

▲ +1.15%

Market Cap $728.71M · Vol 758.17K

Price charts are for members

Interactive price history from intraday to 5 years, on every stock and ETF.

See plans

Key Metrics

P/E Ratio

5.82

FWD: 3.43

Market Cap

$728.71M

Small Cap

Div Yield

N/A

EPS Growth

+390.67%

YoY

RSI (14)

56.35

Momentum

Beta

0.21

vs Market

52W High

$5.76

24.31% below

52W Low

$1.26

246.03% above

Volume

758.17K

Avg 743.59K

P/B

N/A

Price-to-book

ROE

N/A

Return on equity

Free Float

96.57%

Public shares

Shariah Compliance8 STANDARDS

✗ Ironwood Pharmaceuticals, Inc. (IRWD) stock is currently not Shariah compliant

You’ve used your 10 free compliance checks today

Choose a plan

AAOIFI—
Dow Jones Islamic (DJIM)—
FTSE Shariah—
MSCI Islamic—
S&P Shariah—
Al Rajhi—
Alinma—
Albilad—

Unlock the full Shariah report

See which standards it fails, the exact ratios behind the verdict, and halal alternatives.Members see the verdict under each standard, the exact screening ratios, purification and zakat per share. AAOIFI-certified methodology trusted by global Islamic funds.

Which standards does IRWD pass?

The full report shows the verdict under each of the 8 major Shariah standards, with the business-activity and financial-ratio screens behind every one.

Do I need to purify my investment?

Members see the purification amount per share, updated every financial period under the AAOIFI methodology.

Can I calculate zakat for my shares?

Members get zakat per share and a built-in calculator for their exact holding.

Historical Returns

+5.76%

+2.80%

+24.58%

+45.07%

YTD

+30.86%

+212.77%

-53.13%

-65.19%

Financials & Valuation

TTM · Annual

Total Revenue	$296.15M
Net Income	$24.02M
Revenue Growth (YoY)	+32.62%
Gross Margin	100.00%
Operating Margin	40.10%
Net Profit Margin	8.11%
ROE	N/A
ROA · ROIC	18.73% · 11.56%

P/E Ratio	5.82
Forward P/E (FY1)	3.43
PEG Ratio	0.01
P/S	1.85
P/B	N/A
P/FCF	4.32
EPS Growth	+390.67%
Outstanding Shares	165.24M

Technical Indicators

50-Day SMA	$4.13
200-Day SMA	$3.98
RSI (14)	56.35
Beta	0.21
52-Week High	$5.76
52-Week Low	$1.26

Volume Today	758.17K
Avg Daily Volume (30D)	743.59K
Relative Volume	1.02x
Volatility (10D)	36.90
Volatility (30D)	52.58
Free Float	96.57%

Analyst Consensus

BUY

Current Price $4.41

Mean Target $6.10

52W Low$1.26 52W High$5.76

Current

Target

$1.26 $5.76

Current Analyst target

+38.32% upside potential · 4 analysts

Identifiers

ExchangeNASDAQ

FIGIBBG001SNZLM7

ISINUS46333X1081

CountryUSA

Sub-IndustryProprietary & Advanced Pharmaceuticals

Earnings DateNov 9, 2026

TypeStocks

Instrument TypeORD Ordinary Share

Similar Halal Stocks

MRK Merck & Co Inc +1.79% MRK.DE Merck KGaA +2.12% HALO Halozyme Therapeutics, Inc. -0.89% 4151.T Kyowa Kirin Co Ltd -0.29% 326030.KS SK Biopharmaceuticals Co Ltd -0.13%

Company Profile

Ironwood Pharmaceuticals, Inc. is a biotechnology company developing and commercializing life-changing therapies for people living with gastrointestinal (GI), and rare diseases. It is focused on the development and commercialization of GI product opportunities in areas of significant unmet need. LINZESS (linaclotide), its commercial product, is indicated for adult men and women suffering from irritable bowel syndrome with constipation (IBS-C), or chronic idiopathic constipation (CIC), and for pediatric patients ages 6-17 years-old suffering from functional constipation (FC). Linaclotide is available under the trademarked name CONSTELLA to adult men and women suffering from IBS-C or CIC and pediatric patients. The Company is also engaged in advancing apraglutide, a synthetic long-acting peptide analog of glucagon-like peptide-2 (GLP-2), for short bowel syndrome (SBS), patients who are dependent on parenteral support.